Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Thornton

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Parker

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

9397 Crown Crest Blvd, Suite 421
Parker, CO 80138
P: (303) 805-7744

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, CO 80501
P: (303) 684-1900

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lone Tree

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

10107 RidgeGate Parkway, Suite 200
Lone Tree, CO 80124
P: (303) 925-0700

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Littleton

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lakewood

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

11750 W 2nd Place, Med Plaza 1, Suite 150
Lakewood, CO 80228
P: (303) 430-2700

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Englewood

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

499 East Hampden Ave., Suite 450
Englewood, CO 80113
P: (303) 740-8200

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

1800 Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Colorado Springs

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

2312 N Nevada Ave, Suite 400
Colorado Springs, CO 80907
P: (719) 577-2555

More Details View Practice Page
1 2 3 39